M. B. Abdelghani

发表

Age impacts the pattern of care for elderly patients with rectal cancer

C. Brigand, G. Noël, J. Clavier, 2014, International Journal of Colorectal Disease.

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Lecomte, Sophie Gourgou, T. Conroy, 2018, The New England journal of medicine.

Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.

T. Conroy, M. Ychou, E. Assenat, 2018, Journal of Clinical Oncology.

Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial.

E. Assenat, A. Bertaut, F. Bonnetain, 2017 .

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.

T. Conroy, J. Douillard, V. Boige, 2014, The Lancet. Oncology.

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)

F. Bidard, C. Borg, D. Peiffert, 2017, BMC Cancer.

Vitamin B12 Deficiency Associated with Chronic Acid Suppression Therapy

E. Andrès, M. B. Abdelghani, E. Noel, 2003, The Annals of pharmacotherapy.

Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child–Pugh B cirrhosis

C. Lepage, G. Deplanque, V. Bourcier, 2021, Hepatology International.

Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study

O. Bouché, F. Bonnetain, J. Taieb, 2017, Oncotarget.

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)

F. Bidard, C. Borg, D. Peiffert, 2017, BMC Cancer.

cfDNA for accurate determination of RAS and BRAF mutations using OncoBEAM liquid biopsy in metastatic colorectal cancer patients: Results of the real-world multicentric ColoBEAM study.

D. Spaeth, J. Salleron, J. Merlin, 2019, Journal of Clinical Oncology.

Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: results of the FFCD 0904 phase II trial.

A. Lièvre, C. Lepage, X. Mirabel, 2023, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Results of the randomized phase II PRODIGE 28-time UNICANCER study.

V. Boige, O. Bouché, L. Mineur, 2021, Journal of Clinical Oncology.

Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase II study with panitumumab (FFCD 0904).

N. Magné, A. Lièvre, W. Cacheux, 2019, Journal of Clinical Oncology.

Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics

A. Lièvre, C. Lepage, O. Bouché, 2016 .

Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.

O. Bouché, A. Bedjaoui, F. Retornaz, 2018, European journal of cancer.

Baseline nutritional status is prognostic factor after definitive radiochemotherapy for esophageal cancer.

P. Dufour, D. Atlani, J. Clavier, 2014, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.